Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 4, 2007, Pages 433-445

  Findling, Robert L ^a,b   Greenhill, Laurence L ^c   McNamara, Nora K ^a   Demeter, Christine A ^a   Kotler, Lisa A ^c   O'Riordan, Mary Ann ^b   Myers, Carolyn ^b   Reed, Michael D ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; NORADRENALIN; SEROTONIN; VENLAFAXINE;

ABDOMINAL PAIN; ADOLESCENT; AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HOSTILITY; HUMAN; INCREASED APPETITE; INSOMNIA; MALE; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PILOT STUDY; PRESCHOOL CHILD; RATING SCALE; RESTLESSNESS; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACULTY; FEMALE; HUMANS; MALE; NOREPINEPHRINE; PARENTS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 34548690363     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2007.0119     Document Type: Article

References (49)

1. Adler LA, Resnick S, Kunz M, Devinsky O: Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacology Bulletin 31:785-788, 1995.
2. Ahmann PA WS, Olson KA, Theye FW, Van Erem AJ, La-Plant RJ: Placebo-controlled evaluation of Ritalin side effects. Pediatrics 91:1101-1106, 1993.
3. Ambrosini P: Historical development and present status of the schedule for affective disorders and schizophrenia for school-age children (K-SADS). J Am Acad Child Adolesc Psychiatry 39:49-58, 2000.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, D.C., American Psychiatric Association, 1994.
5. Augustin BG, Cold JA, Jann MW: Venlafaxine and Nefazodone, two pharmacologically distinct antidepressants. Pharmacotherapy 17:511-530, 1997.
6. Barkley R, McMurray M, Edelbrock C, Robbins K: Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 86:184-192, 1990.
7. Boulos C, Kutcher S, Gardner D, Young E: An open naturalistic trial of fluoxetine in adolescent and young adults with treatment-resistant major depression. J Child Adolesc Psychopharmacol 2:103-111, 1992.
8. Centers for Disease Control and Prevention C: Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder - United States, Morb Mortal Wkly Rep 54:842-847, 2005.
9. Charlier C, Pinto E, Ansseau M, Plomteux G: Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Hum Psychopharmacol 15:453-459, 2000.
10. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV. New York, The Guilford Press, 1998.
11. Ellingrod V, Perry P: Venlafaxine: A heterocyclic antidepressant. Am J Hosp Pharm 51:3033-3046, 1994.
12. Elsworth JD, Roth RH, Redmond DE Jr.: Relative importance of 3-methoxy-4-hydroxyphenylglycol and 3,4-dihydroxyphenylglycol as norepinephrine metabolites in rat, monkey, and humans. J Neurochem. 4:786-793, 1983.
13. Evans W, Relling M, Petros W, Meyer W, Mirro J, Crom W: Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 45:568-573, 1989.
14. Findling RL, Schwartz MA, Flannery DJ, Manos MJ: Venlafaxine in adults with attention deficit/hyperactivity disorder: An open clinical trial. J Clin Psychiatry 57:184-189, 1996.
15. Findling RL, Reed MD, Myers C, O'Riordan MA, Fiala S, Branicky LA, Waldorf B, Blumer JL: Paroxetine pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 38:952-959, 1999.
16. Findling RL, Myers C, O'Riordan MA, Branicky LA, Pettigrew A, Reed MD, Blumer JL: An open-label dosing study of paroxetine in depressed youths. Curr Therapeut Res 63:588-601, 2002.
17. Greenhill L, Beyer DH, Finkleson J, Shaffer D, Biederman J, Conners CK, Gillberg, C, Huss M, Jensen P, Kennedy JL, Klein R, Rapoport J, Sagvolden T, Spencer T, Swanson JM, Volkow N: Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/Hyperactivity Disorder. J Atten Disord 6:S89-S100, 2002.
18. Gutierrez M, Stimmel G, Aiso J: Venlafaxine: A 2003 update. Clin Ther 25:2138-2154, 2003.
19. Hammad T, Laughren T, Racoosin J: Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332-339, 2006.
20. Harel EH, Brown W: Attention deficit hyperactivity disorder in elementary school children in Rhode Island: associated psychosocial factors and medications used. Clin Pediatr 42:497-503, 2003.
21. Harrison CL, Ferrier N, Young AH: Tolerability of high-dose venlafaxine in depressed patients. J Psychopharmacol 18:200-204, 2004.
22. Harvey AT, Rudolph RL, Preskorn SH: Evidence of the dual mechanism of action of venlafaxine. Arch Gen Psychiatry 57:503-509, 2000.
23. Hedges D, Reimherr FW, Rogers A, Strong R, Wender PH: An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull 31:779-783, 1995.
24. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997.
25. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmoller J: CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104:173-192, 2001.
26. Lee DP, Skolnick JM, Adamson PC: Pediatric phase I trials in oncology: An analysis of study conduct efficiency. J Clin Oncol 23:8431-8441, 2005.
27. Malhotra S, King KH, Welge JA, Brusman-Lovins L, McElroy SL: Venlafaxine treatment of binge eating disorder associated with obesity: A series of 35 patients. J Clin Psychiatry 63:802-806, 2002.
28. Morton W, Sonne S, Verga M: Venlafaxine: A structurally unique and novel antidepressant. Ann Pharmacother 29:387-395, 1995.
29. Mukaddes MN, Abali O: Venlafaxine in children and adolescents with attention deficit hyperactivity disorder. Psychiatry Clin Neurosci 58:92-95, 2004.
30. Muth E, Haskins J, Moyer J, Husbands G, Nielsen S, Sigg E: Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35:4493-4497, 1986.
31. National Institute of Mental Health: Clinical Global Impressions Scale. Psychopharmacol Bull 21:839-843, 1985.
32. Olfson M: New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care 10(4 Suppl):S117-S124, 2004.
33. Olvera RL Pliszka S, Luh J, Tatum R: An open trial of venlafaxine in the treatment of attentiondeficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 6:241-250, 1996.
34. Orvaschel H: Schedule for Affective Disorders and Schizophrenia for School-Age Children- Epidemiologic Version, Fifth Revision Fort Lauderdale (Florida), Nova Southeastern University, 1994.
35. Otton S, Ball S, Cheung S, Inaba T, Rudolph R, Sellers E: Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 41:149-156, 1996.
36. Scahill L, Schwab-Stone M: Epidemiology of ADHD in school-age children. Child Adolesc Psychiatr Clin N Am 9:541-555, 2000.
37. Shaffer D FP, Dulcan MK, Davies M, Piacentini J, Schwab-Stone ME, Lahey, BB BK, Jensen PS, Bird HR, Canino G, Regier DA: The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): Description, acceptability, prevalence rates, and performance in the MECA Study. Methods for the Epidemiology of Child and Adolescent Mental Disorders Study. J Am Acad Child Adolesc Psychiatry 35:865-877, 1996.
38. Sir A, D'Souza R, Uguz S, George T, Vahip S, Hopwood M, Martin AJ, Lam W, Burt: Randomized trial of sertraline versus venlafaxine XR in major depression:efficacy and discontinuation symptoms. J Clin Psychiatry 66:1312-1320, 2005.
39. Spencer T, Biederman J, Kerman K, Steingard R, Wilens T: Desipramine treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Adolesc Psychiatry 32:354-360, 1993.
40. Taylor E, Chadwick O, Heptinstall E, Danckaerts M: Hyperactivity and conduct problems as risk factors for adolescent development. J Am Acad Child Adolesc Psychiatry 35:1213-1226, 1996.
41. Thase M: Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 59:502-508, 1998.
42. van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE: Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit 27:478-483, 2005.
43. Veefkind A, Haffmans P, Hoencamp E: Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 22:202-208, 2000.
44. Weller EB, Weller RA, Davis GP: Use of venlafaxine in children and adolescents: A review of current literature. Depress Anxiety 12(Suppl 1):85-89, 2002.
45. Weltman A, Wood CM, Womack CJ, Davis SE Blumer JL, Alvarez J, Sauer K, Gaesser GA.: Catecholamine and blood lactate responses to incremental rowing and running exercise. J Appl Physiol 76:1144-1149, 1994.
46. Wilens TE Gignac M, Swezey A, Monuteaux MC, Biederman J: Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 45:408-414, 2006.
47. Williams RJ, Goodale L, Shay-Fiddler MA, Gloster SP, Chang SY: Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. Am J Addict 13:381-389, 2004.
48. Wurtman RJ, Fernstrom JD: Control of brain monoamine synthesis by diet and plasma amino acids. Am J Clin Nutr 28:638-647, 1975.
49. Zuvekas SH, Vitiello B, Norquist GS: Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 163:579-585, 2006.